Syndax is seeing unusually fast interest in its two cancer medicines, and patients may stay on treatment longer than many expect—setting up a path to much stronger sales if the momentum holds. But the story hinges on those same two drugs, so any trial, approval, or pricing setback could quickly change the outlook.Read more
Key Takeaways Expanding drug adoption, earlier-line usage, and new regulatory approvals are set to drive broader market access and boost long-term revenue growth. Strong late-stage pipeline, fixed costs, and leading positions in precision oncology create operating leverage and sustained momentum for multi-year profitability.Read more
Key Takeaways Heavy dependence on a few lead assets exposes Syndax to significant clinical, competitive, and regulatory risks that could disrupt future revenue and margin growth. Sustained expansion and profitability rely on overcoming payer, regulatory, and clinical adoption hurdles, with high R&D costs posing ongoing pressure on margins.Read more
No trending discussion available.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
